It is important to know what is happening in clinical practice so when I talk with the family of a child I can to tell them what to expect. How are patients getting and tolerating the medication? What is their response?
– Reena Rastogi, MD
Phoenix Children’s Hospital, Phoenix, AZ
These are safe, easy-to-use, targeted therapeutics for patients with migraine. Consider using them in patients with a migraine diagnosis.
– Jessica Ailani, MD
Georgetown University, Washington, DC
These are treatments developed for migraine, that work in migraine, and that will transform the discussion we have with patients because we can say, “here’s a drug for migraine.” The early open-label extension data support long-term efficacy and safety. I encourage neurologists to learn about this, because their patients will. Be prepared for the beautiful simplicity of people getting well without any additional theme that needs to be addressed.
– Peter Goadsby, MD, PhD
King’s College, London, England
Long-term outcomes, safety profile, and dosages, especially since there is no indication for pediatrics yet. For pediatric patients with headache refractory to treatment, when can I use this safely?
– Cristina Victorio, MD
Akron Children’s Hospital, Akron, OH
Will people on CGRP-based preventative therapy also be able to take and benefit from CGRP-antagonist abortive therapy; and if so, will it have efficacy? This is particularly interesting in people who are not able to take triptans (eg, those with cardiovascular contraindications) or don’t respond to triptans.
– Paul Mathew, MD Harvard Medical School, Boston, MA
When to prescribe the drugs and for whom— for example, when someone is on botulinum toxin already, can we consider it a first-line treatment, adjunctive treatment, or second-line treatment?
– Henry Hooker, MD
Oak Ridge, Tennessee
